Dietary energy balance modulates ovarian cancer progression and metastasis

Oncotarget

Volumn 5, Issue 15, 2014, Pages 6063-6075

  Al Wahab, Zaid ^a   Tebbe, Calvin ^b   Chhina, Jasdeep ^b   Dar, Sajad A ^b   Morris, Robert T ^a   Ali Fehmi, Rouba ^c   Giri, Shailendra ^b   Munkarah, Adnan R ^b   Rattan, Ramandeep ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AMPK; Calorie restriction; Energy balance; High energy diet; MTOR; Ovarian cancer; SIRT1

Indexed keywords

ADIPONECTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INTERLEUKIN 6; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; SIRTUIN 1; SOMATOMEDIN C; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CALORIC RESTRICTION; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; DIAPHRAGM; ENERGY BALANCE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; INTESTINE; KIDNEY; LIVER; METASTASIS; MOUSE; NONHUMAN; OVARY CARCINOMA; PERITONEUM; SPLEEN; ANIMAL; C57BL MOUSE; DIET THERAPY; DISEASE COURSE; HUMAN; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE PROGRESSION; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84906246589     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2168     Document Type: Article

References (89)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29.
2. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A and Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc. 2007; 82(6):751-770.
3. Patel AC, Nunez NP, Perkins SN, Barrett JC and Hursting SD. Effects of energy balance on cancer in genetically altered mice. J Nutr. 2004; 134(12 Suppl):3394S-3398S.
4. Malin A, Matthews CE, Shu XO, Cai H, Dai Q, Jin F, Gao YT and Zheng W. Energy balance and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005; 14(6):1496-1501.
5. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR and Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001; 92(4):720-729.
6. Platz EA, Leitzmann MF, Michaud DS, Willett WC and Giovannucci E. Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res. 2003; 63(23):8542-8548.
7. Austin H, Austin JM, Jr., Partridge EE, Hatch KD and Shingleton HM. Endometrial cancer, obesity, and body fat distribution. Cancer Res. 1991; 51(2):568-572.
8. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Rubinson DA, Stampfer MJ, Giovannucci EL and Wolpin BM. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013; 31(33):4229-4234.
9. Chen Y, Wang X, Wang J, Yan Z and Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer. 2012; 48(14):2137-2145.
10. Moore T, Beltran L, Carbajal S, Strom S, Traag J, Hursting SD and DiGiovanni J. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res (Phila). 2008; 1(1):65-76.
11. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ and Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995; 122(5):327-334.
12. Dai Z, Xu YC and Niu L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol. 2007; 13(31):4199-4206.
13. Stewart JW, Koehler K, Jackson W, Hawley J, Wang W, Au A, Myers R and Birt DF. Prevention of mouse skin tumor promotion by dietary energy restriction requires an intact adrenal gland and glucocorticoid supplementation restores inhibition. Carcinogenesis. 2005; 26(6):1077-1084.
14. Hursting SD, Smith SM, Lashinger LM, Harvey AE and Perkins SN. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis. 2010; 31(1):83-89.
15. Xie L and Wang W. Weight control and cancer preventive mechanisms: role of insulin growth factor-1-mediated signaling pathways. Exp Biol Med (Maywood). 2013; 238(2):127-132.
16. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012; 12(3):159-169.
17. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM and Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004; 363(9418):1346-1353.
18. Memmott RM and Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009; 21(5):656-664.
19. Osaki M, Oshimura M and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004; 9(6):667-676.
20. Barb D, Williams CJ, Neuwirth AK and Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007; 86(3):s858-866.
21. Dalamaga M, Diakopoulos KN and Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012; 33(4):547-594.
22. Garofalo C and Surmacz E. Leptin and cancer. J Cell Physiol. 2006; 207(1):12-22.
23. Yang T, Fu M, Pestell R and Sauve AA. SIRT1 and endocrine signaling. Trends Endocrinol Metab. 2006; 17(5):186-191.
24. Metoyer CF and Pruitt K. The role of sirtuin proteins in obesity. Pathophysiology. 2008; 15(2):103-108.
25. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, Gorospe M, de Cabo R and Sinclair DA. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004; 305(5682):390-392.
26. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, Steele AD, Crowe H, Marmor S, Luo J, Gu W and Guarente L. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell. 2007; 6(6):759-767.
27. Ramsey KM, Mills KF, Satoh A and Imai S. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell. 2008; 7(1):78-88.
28. Ford J, Jiang M and Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 2005; 65(22):10457-10463.
29. Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T, Inomata M, Miwa T, Matsui S, Usui I, Urakaze M, Matsuya Y, Ogawa H, Sakurai H, Saiki I and Tobe K. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep. 2012; 27(6):1726-1732.
30. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP and Sinclair DA. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One. 2008; 3(4):e2020.
31. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol. 2007; 47:185-210.
32. Hardie DG and Alessi DR. LKB1 and AMPK and the cancer-metabolism link -ten years after. BMC Biol. 2013; 11:36.
33. Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67(22):10804-10812.
34. Rattan R, Giri S, Hartmann LC and Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011; 15(1):166-178.
35. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F and Ido Y. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab. 2010; 298(4):E751-760.
36. Ghosh HS, McBurney M and Robbins PD. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One. 2010; 5(2):e9199.
37. Blagosklonny MV. Rapamycin extends life-and health span because it slows aging. Aging (Albany NY). 2013; 5(8):592-598.
38. van Kruijsdijk RC, van der Wall E and Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009; 18(10):2569-2578.
39. Saharinen P, Eklund L, Pulkki K, Bono P and Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011; 17(7):347-362.
40. Wada H, Ura S, Kitaoka S, Satoh-Asahara N, Horie T, Ono K, Takaya T, Takanabe-Mori R, Akao M, Abe M, Morimoto T, Murayama T, Yokode M, Fujita M, Shimatsu A and Hasegawa K. Distinct characteristics of circulating vascular endothelial growth factor-a and C levels in human subjects. PLoS One. 2011; 6(12):e29351.
41. Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE and Hankinson SE. Obesity, weight gain, and ovarian cancer. Obstet Gynecol. 2002; 100(2):288-296.
42. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH, Risch HA, Yu H, Doherty JA, Chang-Claude J, Hein R, Nickels S, Wang-Gohrke S, et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer. 2013; 20(2):251-262.
43. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K and Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011; 17(11):1498-1503.
44. Clark R, Krishnan V, Schoof M, Rodriguez I, Theriault B, Chekmareva M and Rinker-Schaeffer C. Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models. Am J Pathol. 2013; 183(2):576-591.
45. Tebbe C CJ, Dar S, Sarigiannis K, Giri S, Munkarah A and Rattan R. Metformin limits the adipocyte tumor promoting effect on ovarian cancer Oncotarget. 2014; Accepted.
46. Mizuno NK, Rogozina OP, Seppanen CM, Liao DJ, Cleary MP and Grossmann ME. Combination of intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors. Cancer Prev Res (Phila). 2013; 6(6):540-547.
47. Li HJ, Che XM, Zhao W, He SC, Zhang ZL, Chen R, Fan L and Jia ZL. Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop. Oncol Rep. 2013; 30(5):2153-2160.
48. Kim WG, Park JW, Willingham MC and Cheng SY. Dietinduced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model. Endocrinology. 2013; 154(8):2936-2947.
49. Huang M, Narita S, Inoue T, Tsuchiya N, Satoh S, Nanjo H, Sasaki T and Habuchi T. Diet-induced macrophage inhibitory cytokine 1 promotes prostate cancer progression. Endocr Relat Cancer. 2014; 21(1):39-50.
50. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM and Stampfer MJ. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004; 96(7):546-553.
51. Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak MN, Ma J and Fuchs CS. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 2007; 16(10):2101-2109.
52. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8(12):915-928.
53. Renehan AG, Frystyk J and Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006; 17(8):328-336.
54. Beauchamp MC, Yasmeen A, Knafo A and Gotlieb WH. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol. 2010; 2010:257058.
55. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE and Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998; 351(9113):1393-1396.
56. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH and Pollak M. Plasma insulinlike growth factor-I and prostate cancer risk: a prospective study. Science. 1998; 279(5350):563-566.
57. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO and Trichopoulos D. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst. 1998; 90(12):911-915.
58. Karasik A, Menczer J, Pariente C and Kanety H. Insulinlike growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 1994; 78(2):271-276.
59. Weigang B, Nap M, Bittl A and Jaeger W. Immunohistochemical localization of insulin-like growth factor 1 receptors in benign and malignant tissues of the female genital tract. Tumour Biol. 1994; 15(4):236-246.
60. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-562.
61. Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008; 27(50):6473-6488.
62. Dobbin ZC and Landen CN. The importance of the PI3K/ AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013; 14(4):8213-8227.
63. Stattin P, Lukanova A, Biessy C, Soderberg S, Palmqvist R, Kaaks R, Olsson T and Jellum E. Obesity and colon cancer: does leptin provide a link? Int J Cancer. 2004; 109(1):149-152.
64. Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ, Troncoso P, Scardino PS, Wheeler TM, Amos CI and Spitz MR. Leptin and prostate cancer. Prostate. 2001; 46(1):62-67.
65. Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, Yu JC and Sun CA. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009; 100(4):578-582.
66. Chen C, Chang YC, Lan MS and Breslin M. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways. Int J Oncol. 2013; 42(3):1113-1119.
67. Uddin S, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P and Al-Kuraya KS. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer. 2009; 8:74.
68. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T and Cao Y. Adiponectininduced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004; 101(8):2476-2481.
69. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS and Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate. 2008; 68(14):1592-1598.
70. Gregor MF and Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011; 29:415-445.
71. Lu H, Ouyang W and Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006; 4(4):221-233.
72. Eder K, Baffy N, Falus A and Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res. 2009; 58(11):727-736.
73. Guo Y, Xu F, Lu T, Duan Z and Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012; 38(7):904-910.
74. Byrne AM, Bouchier-Hayes DJ and Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005; 9(4):777-794.
75. Hursting SD, Dunlap SM, Ford NA, Hursting MJ and Lashinger LM. Calorie restriction and cancer prevention: a mechanistic perspective. Cancer Metab. 2013; 1(1):10.
76. Lanza-Jacoby S, Yan G, Radice G, LePhong C, Baliff J and Hess R. Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer. Exp Biol Med (Maywood). 2013; 238(7):787-797.
77. Moore T, Beltran L, Carbajal S, Hursting SD and DiGiovanni J. Energy balance modulates mouse skin tumor promotion through altered IGF-1R and EGFR crosstalk. Cancer Prev Res (Phila). 2012; 5(10):1236-1246.
78. Powolny AA, Wang S, Carlton PS, Hoot DR and Clinton SK. Interrelationships between dietary restriction, the IGF-I axis, and expression of vascular endothelial growth factor by prostate adenocarcinoma in rats. Mol Carcinog. 2008; 47(6):458-465.
79. Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R, Jurgensmeier JM, Giavazzi R and Belotti D. Vascular endothelial growth factor C promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol. 2014; 184(4):1050-1061.
80. Gawrychowski K, Szewczyk G, Skopinska-Rozewska E, Malecki M, Barcz E, Kaminski P, Miedzinska-Maciejewska M, Smiertka W, Szukiewicz D and Skopinski P. The angiogenic activity of ascites in the course of ovarian cancer as a marker of disease progression. Dis Markers. 2014; 2014:683757.
81. Canto C and Auwerx J. Calorie restriction: is AMPK a key sensor and effector? Physiology (Bethesda). 2011; 26(4):214-224.
82. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011; 25(18):1895-1908.
83. Blagosklonny MV. M(o)TOR of aging: MTOR as a universal molecular hypothalamus. Aging (Albany NY). 2013; 5(7):490-494.
84. Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, Strong R, Bokov A, Javors MA, Ikeno Y, Hubbard G, Hasty P and Sharp ZD. Rapamycin extends life span of Rb1+/-mice by inhibiting neuroendocrine tumors. Aging (Albany NY). 2013; 5(2):100-110.
85. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV and Gudkov AV. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/-mice. Aging (Albany NY). 2012; 4(10):709-714.
86. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV and Antoch MP. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/-mice by delaying carcinogenesis. Aging (Albany NY). 2012; 4(10):715-722.
87. Liu Y, Huang Y, Wang Z, Li X, Louie A, Wei G and Mao JH. Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development. Aging (Albany NY). 2013; 5(2):111-119.
88. Blagosklonny MV and Campisi J. Cancer and aging: more puzzles, more promises? Cell Cycle. 2008; 7(17):2615-2618.
89. Rattan R, Graham RP, Maguire JL, Giri S and Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011; 13(5):483-491.